KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosisOmar S. Al‐Odat, Manoj K. Pandey|Frontiers in Pharmacology|2024Cited by 4